The company announced the Neuratia Research Fellows Program 2026 on July 1, a fully sponsored six-month fellowship open to researchers working across neuroscience, neurotechnology, artificial intelligence, computational neuroscience, and precision brain health. Applications are open now and close on July 31, 2026.

Each fellowship is valued at an estimated $5,000 USD. That covers access to the company’s cloud-based research platform and a range of support services, all provided at no cost to selected fellows.

How does it work?

Fellows accepted into the program get access to ONYX Research Cloud, Neuratia Labs’ cloud-native neuroinformatics platform. Beyond the software, the program wraps a full layer of support around each researcher. Over the six-month period, participants receive:

• Individual mentorship from researchers and subject-matter experts
• Help with study design, statistical analysis, and computational neuroscience methods
• Guidance on writing and publishing research, including collaborative authorship opportunities
• A Neuratia Research Fellowship Certificate and a digital credential
• Membership in Neuratia Labs’ global neuroscience research community

The program is open to a wide range of applicants. PhD candidates, postdoctoral researchers, MBBS students, MD residents, faculty members, clinical researchers, early-career investigators, and independent scientists are all eligible, as long as their work touches on neuroscience or a related field.

Researchers who want to apply or find out more can visit NeuratiaLabs.com/fellows.

Why does it matter?

Affaan Shaikh, Founder and CEO of Neuratia Labs, put it plainly: “Outstanding researchers are often constrained by fragmented data, inconsistent methodologies, and limited computational resources.” That is a well-documented problem in neuroscience, where replication failures and inconsistent data practices have been a persistent concern for years.

By pairing researchers with cloud infrastructure and methodological support, the program takes aim at two of the biggest practical obstacles in the field: access to computing power and access to expertise. For early-career researchers or those working in under-resourced institutions, those barriers can be the difference between a study that gets published and one that stalls out.

The fellowship is also structured around reproducibility and transparency, two areas where neuroscience has faced real scrutiny. Building those principles into the program from the start is a meaningful design choice.

The context

Neuroscience is in an interesting moment. Brain imaging, wearable biosensors, and AI-assisted analysis are producing more data than ever before. But generating data is not the same as doing good science, and the field has been wrestling with questions about how to standardize methods, share data responsibly, and move findings from the lab toward clinical use.

Corporate-sponsored research fellowships are not new, but they are becoming more common as biotech and health tech companies look to build relationships with the academic research community. The model works best when the support is genuinely useful and the company’s interests align with good science. In this case, Neuratia Labs has a clear interest in demonstrating what its ONYX platform can do, while researchers get free access to tools they might not otherwise afford.

The 2026 cohort is the first the program has run, so there is limited track record to evaluate. What happens to the research produced, who retains ownership of the data, and how fellows rate the experience will be worth watching as the program matures.

The post Neuratia Labs opens applications for its 2026 fully funded research fellows program appeared first on DH Arab.

The move reflects a broader push by Aster DM Healthcare, the parent company, to bring specialized care closer to patients rather than concentrating it in capital cities. Sohar is a major population and industrial hub in northern Oman, and healthcare demand there has been growing steadily.

Oman’s Ministry of Health has backed the expansion, with Undersecretary Dr. Ahmed bin Salim Al-Mandhari saying the initiative aligns with the country’s goal of “strengthening healthcare accessibility and integrating advanced medical technologies within the national system.”

What’s the news?

Aster Al Raffah has launched its second Walk Again Advanced Robotic Rehabilitation Centre in Oman, located in Sohar. The first center opened in Muscat and is described by the company as a flagship facility.

The Sohar center uses AI-powered robotic systems to deliver what the company calls precise, repetitive therapy. The technology is designed to support motor recovery by working with the brain’s ability to rewire itself, a process known as neuroplasticity. Clinicians can also track patient progress in real time to adjust treatment as it goes.

The center will treat a wide range of conditions, including:

• Spinal cord injury and traumatic brain injury
• Stroke-related impairments
• Multiple sclerosis and motor neuron disease
• Cerebral palsy and muscular dystrophy
• Autism spectrum disorder
• Movement disorders, including ataxia and dystonia
• Alzheimer’s disease and dementia

Beyond physical rehabilitation, the facility also covers neurology, spine care, sports medicine, and mental wellbeing, aiming to treat patients across multiple needs in one place.

Why does it matter?

Robotic rehabilitation is still relatively rare in the Gulf region. Most advanced facilities of this kind are concentrated in a handful of urban centers, which means patients in smaller cities often have to travel long distances for care or go without it entirely.

Opening a center in Sohar changes that calculation for people in northern Oman. Spinal cord injuries, strokes, and conditions like cerebral palsy require consistent, long-term therapy to show results. When patients have to travel hours for each session, they often drop out of treatment early. Local access makes it far more likely they’ll complete their rehabilitation.

There’s also a broader signal here. Aster expanding this program to a second city suggests the Muscat center has been performing well enough to justify replication. That matters because it gives other healthcare providers in the region a proof point that demand for this kind of specialized robotic care exists outside major capitals.

The context

Aster DM Healthcare is one of the largest private healthcare groups operating across the Gulf and India. The Walk Again program sits within a wider trend of hospitals investing in robotic and AI-assisted therapy, a category that has grown quickly since the pandemic accelerated interest in technology-driven care.

Robotic rehabilitation systems, such as exoskeletons and motion-assisted platforms, have been in clinical use for over a decade in Europe and North America. Their adoption in the Middle East has been slower, partly because of cost and partly because of limited specialist staff trained to use them. The fact that Oman now has two such centers, and that the government is publicly endorsing the expansion, suggests that gap is closing.

Oman has been working to reduce dependence on medical referrals abroad, particularly for complex neurological cases. Investments like this one support that goal by keeping patients and their families in-country for treatment that previously may have required a trip to Europe or Southeast Asia.

The post Aster opens second robotic rehabilitation center in Oman, this time in Sohar appeared first on DH Arab.

The partnership gives both organizations a formal framework to expand Qatar’s clinical trial activity, strengthen the infrastructure needed to evaluate new drugs and medical technologies, and give local researchers more exposure to international studies and emerging science.

For HMC, the deal is part of a broader push to position Qatar as a serious player in global medical research, in line with the country’s National Health Strategy 2024-2030 and its longer-term Qatar National Vision 2030.

How will it work?

The MoU covers several distinct areas of cooperation between HMC and Boehringer Ingelheim:

• Clinical trials: The two organizations will work to strengthen HMC’s Clinical Trials Unit, with the goal of attracting more international studies to Qatar and giving local researchers greater access to global networks.
• Health technology assessment (HTA): HMC will receive support to build out its HTA capabilities, including the technical skills and infrastructure needed to assess the clinical, economic, and social value of new medicines, devices, and digital health tools.
• Research visibility: HMC researchers will gain better access to information on emerging therapies and scientific developments, helping the organization align its research priorities with where medicine is heading.
• Workforce development: The agreement includes capacity-building efforts to improve the skills of healthcare professionals involved in research and evidence-based decision-making.

Ali Al Janahi, Assistant Managing Director of HMC, said the collaboration is about “expanding opportunities for clinical trials, enhancing research capabilities, and strengthening expertise” to improve patient outcomes in Qatar.

Why does it matter?

Health technology assessment is still a relatively young discipline in much of the Gulf region. As governments across the Middle East try to move away from blanket reimbursement of new drugs and toward more selective, evidence-based purchasing decisions, having trained HTA professionals and solid infrastructure matters a great deal. This partnership directly targets that gap.

On the clinical trials side, Qatar has historically had limited participation in large international studies. Attracting more of those trials has real benefits: patients get earlier access to new treatments, local researchers build their careers and reputations, and the country’s broader scientific base grows stronger.

Anas Ahmad Hamad, Deputy Chief of Drug Supply at HMC and lead of the National HTA and Innovation Regulation Program, said the goal is to build “sustainable HTA infrastructure” that supports “responsible access to innovation” rather than simply adding bureaucratic process.

The context

Boehringer Ingelheim is one of the world’s largest privately held pharmaceutical companies, with a strong presence across therapeutic areas including cardiovascular disease, diabetes, and respiratory conditions. The company has been expanding its partnerships across the Middle East and Africa region in recent years, reflecting growing interest from global pharma in markets that are investing heavily in healthcare modernization.

HMC runs most of Qatar’s public hospitals and specialist centers, making it the logical anchor partner for any large-scale research or healthcare development initiative in the country. Qatar has invested significantly in healthcare infrastructure in recent years, and deals like this one are part of a conscious effort to shift from building physical capacity to building scientific and research capacity.

The agreement also fits a wider regional trend. Saudi Arabia, the UAE, and Qatar are all competing to attract pharmaceutical investment, clinical research activity, and healthcare innovation, and formal partnerships with major global companies are one of the key tools they are using to do it.

The post Qatar’s main hospital network partners with Boehringer Ingelheim to build clinical research capacity appeared first on DH Arab.

SAKINA, the mental health network run by SEHA (a subsidiary of PureHealth, the Middle East’s largest healthcare group), has signed a memorandum of understanding with SpeechCare Centre, a specialist in speech therapy and neurodevelopmental care. The agreement focuses on building evidence-based clinical frameworks for SAKINA’s Digital Wellbeing Centre in Abu Dhabi.

The partnership reflects a broader push in the UAE to move beyond reactive healthcare and build preventive, research-led models that address emerging health challenges before they become crises.

How does it work?

Under the agreement, the two organizations will work together on several fronts:

• Designing research protocols specifically focused on digital behaviors and their effects on wellbeing
• Developing clinical frameworks that give practitioners clear tools for assessment, referral, and follow-up
• Creating training programs and certifications to help professionals implement those frameworks
• Adapting everything to fit the cultural context of the UAE community

The clinical frameworks will give SAKINA’s Digital Wellbeing Centre a structured, consistent approach to measuring and responding to digital wellbeing issues, particularly in children.

“Digital wellbeing is one of the most significant challenges and opportunities in contemporary mental health,” said Dr. Zain Ali Al Yafai, CEO of SAKINA. “We are developing research-led clinical frameworks that translate knowledge into practical care to support children and families in a healthier, more balanced digital environment.”

Why does it matter?

Screen time and digital behavior have moved from a parenting debate to a clinical concern. Research consistently links excessive or unstructured screen use in children to delays in language development, attention difficulties, and mental health problems. Yet most healthcare systems still lack standardized tools to assess and respond to these issues.

That’s the gap this partnership is trying to close. By combining SpeechCare’s expertise in communication and neurodevelopment with SAKINA’s mental health infrastructure, the two organizations are trying to build something clinicians can actually use day to day.

Farah Al Qaissieh, CEO of SpeechCare Abu Dhabi, framed it in straightforward terms: “We aim to strengthen scientific research, build professional capacity and help ensure every child has a genuine opportunity to succeed in their communication journey.”

The context

Abu Dhabi has made healthcare integration a policy priority in recent years, pushing for models that connect research, clinical practice, and community health rather than treating them as separate tracks. This partnership fits that direction.

PureHealth, SAKINA’s parent company, has been expanding its footprint across specialized care in the UAE. SpeechCare, meanwhile, works at the intersection of speech, language, and neurodevelopmental support, an area that increasingly overlaps with digital health concerns as more children present with communication delays linked to early and heavy device use.

The collaboration is also part of a wider regional conversation. Governments and health authorities across the Gulf are grappling with how to respond to rising rates of anxiety, attention disorders, and developmental delays in children, and many are starting to look at digital behavior as a contributing factor worth addressing clinically, not just in public awareness campaigns.

The post Abu Dhabi mental health network teams up with speech therapy clinic to tackle digital wellbeing appeared first on DH Arab.

Under the deal, the two organisations will explore two concrete projects. The first is an AI-powered obesity care model. The second is a dedicated Alzheimer’s Disease Centre of Excellence based in Abu Dhabi. Neither project has a confirmed launch date yet, but the MoU sets the formal groundwork for both.

The signing brings together one of the world’s largest drug makers and a government health regulator that has spent years building out Abu Dhabi’s data and genomics infrastructure. That combination of pharmaceutical expertise and population-level health data is what both sides say makes this partnership worth pursuing.

How will it work?

The MoU is a framework agreement, meaning the specific details of each project will be worked out over time. But the broad outlines are clear:

• AI-enabled obesity model: The plan is to use artificial intelligence alongside population health data to build a more personalised approach to obesity care, moving beyond one-size-fits-all treatment.
• Alzheimer’s Centre of Excellence: Abu Dhabi would host a specialist centre focused on Alzheimer’s research, diagnosis and treatment, drawing on the emirate’s existing clinical infrastructure.

Leena Aziz, Eli Lilly’s Senior Director for Corporate and Government Affairs in the Gulf, said the partnership aims to bring together AI, population health insights and clinical science to address both conditions. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, pointed to Abu Dhabi’s existing precision medicine capabilities, including population-scale genomics and advanced health data systems, as the foundation for the work.

Why does it matter?

Obesity rates across the Gulf have climbed sharply over the past two decades, driven by lifestyle changes, rapid urbanisation and diet shifts. The UAE is no exception. Alzheimer’s, meanwhile, is a growing concern as the population ages, and specialist care for the condition remains limited across much of the Middle East.

For Eli Lilly, the timing is significant. The company has become one of the most talked-about names in pharma thanks to its GLP-1 drugs, including tirzepatide (Mounjaro), which are now used widely for both diabetes and obesity. Expanding its footprint in the Gulf through a government-backed partnership gives Lilly a direct line into a high-growth healthcare market.

For Abu Dhabi, the deal fits a broader push to position the emirate as a hub for life sciences and medical innovation, not just a consumer of treatments developed elsewhere.

The context

BIO International is one of the largest biotech and pharma conventions in the world, and it has become a regular venue for governments and companies to announce health partnerships. Abu Dhabi has signed several deals at similar events in recent years as part of its strategy to attract life sciences investment.

The emirate has built a significant health data infrastructure through programs like the Abu Dhabi Genome Programme, which has collected genomic data from tens of thousands of residents. That kind of population-level data is exactly what AI-driven healthcare models need to work effectively, and it is a genuine differentiator that Abu Dhabi can offer potential partners like Lilly.

Eli Lilly’s broader pipeline also includes donanemab, an Alzheimer’s treatment that received FDA approval in 2024. Whether that drug plays a role in the Abu Dhabi centre has not been confirmed, but it adds weight to why an Alzheimer’s-focused collaboration with Lilly makes sense right now.

The post Abu Dhabi partners with Eli Lilly to tackle obesity and Alzheimer’s with AI appeared first on DH Arab.

The study will test HT-4253, Halia’s experimental drug, in people who carry the APOE4 gene variant. That variant is the strongest known genetic risk factor for late-onset Alzheimer’s. The key word here is ‘asymptomatic’: researchers are not waiting for cognitive decline to show up. They want to intervene before the disease takes hold.

What makes this trial unusual is where the participants come from. Instead of standard recruitment, eligible individuals will be identified through the Emirati Genome Programme (EGP), a national database of genetic data from the UAE population. Those who match the criteria will receive a text message inviting them to screening. It is a model that turns a national genomic database into a direct pipeline for clinical research.

How does it work?

The process runs in a few distinct steps:

• Researchers use the EGP database to identify people who may carry the APOE4 variant and meet the trial’s eligibility criteria
• The Department of Health Abu Dhabi contacts those individuals by text message to invite them to screening
• Eligible participants go through genetic counseling before any trial enrollment
• Those who qualify are enrolled in the trial and receive HT-4253, Halia’s investigational therapy

The Department of Health Abu Dhabi is providing regulatory oversight and says all data use complies with applicable privacy and data protection rules. The EGP data is not being handed over to third parties; the outreach and screening process is managed within the existing regulatory framework.

Why does it matter?

Alzheimer’s affects more than 55 million people worldwide. That number is expected to nearly triple by 2050, and there is still no approved treatment that stops the disease before it starts. Most clinical trials enroll people after symptoms appear, which many researchers believe is too late for meaningful intervention.

This trial takes a different approach: use genetics to find people at risk before damage accumulates, then test whether a drug can make a difference at that earlier stage. If it works, it could help shift Alzheimer’s care from treatment toward prevention.

There is also a representation problem in global genomics research. The vast majority of large genomic studies have been conducted on populations of European descent, which limits how broadly findings can be applied. The EGP is one of the few population-scale datasets built around a Middle Eastern population, and including that data in clinical research helps address a real gap in the global evidence base.

The context

The Emirati Genome Programme was launched in 2019 with a goal of mapping the genomes of all UAE nationals. It is one of the largest national genomics initiatives in the world by population coverage, and Abu Dhabi has positioned it as a long-term health infrastructure investment rather than a research project with a defined end date.

M42, the Abu Dhabi-based health company that includes IROS, has been building out clinical and data infrastructure designed to connect genomic data with real-world research. IROS was set up specifically to run biomarker-driven trials of the kind this Alzheimer’s study represents.

Halia Therapeutics’ approach to drug development centers on what its team calls genetic resilience: studying people who carry high-risk gene variants but do not develop the expected disease, then trying to understand and replicate that biological protection. The company has established a physical presence in Abu Dhabi as part of this collaboration, citing the EGP’s data scale and the integrated clinical infrastructure as the main reasons for choosing the UAE as a trial location.

For Abu Dhabi, the trial is an early test of whether years of investment in national genomic data can translate into something clinically useful. If the model works, it could attract more international biotech companies looking for genetically characterized populations that are currently underrepresented in global research.

The post Abu Dhabi launches first genomics-driven Alzheimer’s trial using national DNA database appeared first on DH Arab.

The deal was announced at the BIO International Convention 2026 in San Diego. Abu Dhabi Biobank is a joint initiative between the Department of Health Abu Dhabi (DoH) and M42, a global health company. BioTwin brings a longitudinal biomarker platform that combines home-based blood collection, multi-biomarker analysis, and AI modeling to build a continuously updated digital picture of a person’s health.

Together, the two organizations plan to connect BioTwin’s individual health profiles with Abu Dhabi Biobank’s genomic, clinical, and biological data to generate earlier warning signals for disease, design prevention strategies, and deliver more personalized care at population scale.

How will it work?

BioTwin’s platform works by collecting biological data over time, not just at a single point. Here’s how the system is designed:

• Patients collect blood samples at home using dried blood spot kits, which are then analyzed for multiple biomarkers.
• AI models use that data to build a “virtual human twin,” a digital representation of an individual’s health trajectory.
• Over time, the platform tracks changes and generates longitudinal insights, spotting patterns that might indicate early disease or elevated risk.
• Abu Dhabi Biobank adds another layer by linking these profiles to genomic data, clinical records, and population-scale health information.

The first application will focus on multi-cancer screening. If that goes well, the partnership plans to expand into preventive health more broadly, including health optimization and personalized care programs.

Why does it matter?

Early detection saves lives. That’s the simple reason this kind of partnership matters. Most cancers, and many chronic diseases, are far easier to treat when caught early, but current healthcare systems are largely built around responding to symptoms rather than anticipating them.

What makes this deal notable is the combination of assets involved:

• Abu Dhabi Biobank has access to high-quality biological materials, governed data infrastructure, and real-world population data at scale.
• BioTwin brings a consumer-friendly collection method and AI modeling that can track health changes over months and years.
• The UAE’s regulatory environment is designed to support fast iteration and real-world implementation, which matters when you’re trying to move from research to clinical deployment.

Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi, described the emirate’s ambition plainly: “This model creates the foundation for predictive, preventive and personalised future of health, resulting in earlier intervention at population scale that builds a healthier community.”

Louis-Philippe Noel, Founder and CEO of BioTwin, said the partnership is “a major step” in making early detection and personalized health optimization accessible through virtual twin technology.

The context

Abu Dhabi has been building its life sciences infrastructure for years. The city has invested heavily in genomics through the M42-backed Biobank, in clinical research capacity, and in regulatory frameworks designed to attract health tech companies looking to run real-world pilots at scale.

Globally, the virtual human twin concept is gaining serious traction. The idea, using continuously updated digital models of individual patients to guide clinical decisions, has moved from academic research into commercial health platforms over the past few years. Several companies are now racing to make the technology practical and affordable outside of hospital settings.

The home-based blood collection angle is also significant. One of the biggest barriers to longitudinal health monitoring is convenience. If people have to visit a clinic every few months for tests, most won’t. Dried blood spot collection, done at home and mailed to a lab, removes that friction and makes sustained monitoring far more realistic for large populations.

Albarah El-Khani, Chief Operating Officer for Integrated Health Solutions at M42, summed up the opportunity: “Abu Dhabi Biobank provides not only access to high-quality biological materials, but also to data, governance and translational pathways.” That combination, good data, clear governance, and a path to clinical deployment, is exactly what health tech companies need to move from concept to practice.

The post Abu Dhabi Biobank partners with BioTwin to bring AI ‘virtual human twin’ technology to the UAE appeared first on DH Arab.

The partnership will use Abu Dhabi’s existing genomics infrastructure to study how genetic and population-level factors affect disease development and how patients respond to treatment. Researchers will focus on a wide range of conditions, including cardiovascular disease, diabetes, cancer, rare diseases, neurological disorders, metabolic diseases, fibrotic diseases, eye conditions, and immunological conditions.

The MoU was signed by Dr. Mohamed Al Ameri, Division Director of Genome and Biobank at the Department of Health, and Ghaleb Al Ahdab, Head of Public and Government Affairs UAE and Near East at Boehringer Ingelheim. Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi, was also present at the ceremony.

How will it work?

The collaboration will draw on Abu Dhabi’s genomics programs and research infrastructure to generate scientific insights that neither organization could easily produce alone. While the MoU sets out the intent to work together, the two sides will now explore specific research opportunities within the agreed focus areas.

The goal is to build a clearer picture of:

• Which genetic factors make certain populations more susceptible to specific diseases
• How those factors vary across Abu Dhabi’s population
• How patients with different genetic profiles respond to existing and future treatments

Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health Abu Dhabi, said the collaboration reflects the emirate’s commitment to put its genomics capabilities to work. “The knowledge we generate will inform future research, advance personalised healthcare approaches, and contribute to more effective, sustainable health outcomes for Abu Dhabi and the wider region,” she said.

Why does it matter?

Precision medicine relies on understanding how individual biology shapes health and disease. That requires large, well-structured datasets and the infrastructure to analyze them. Abu Dhabi has spent years building exactly that, and this deal gives Boehringer Ingelheim access to those resources while giving Abu Dhabi a link to a global drug developer’s research pipeline.

For patients, the practical payoff would be treatments better matched to their biology rather than one-size-fits-all approaches. That matters especially in a region where some genetic variants common in Middle Eastern populations are underrepresented in global clinical research.

Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said the partnership reflects a shared focus on understanding disease prevalence and addressing unmet medical needs. “Abu Dhabi has strategically invested in many of the critical enablers of precision medicine, from large-scale genomics programs and advanced research infrastructure to a clear national vision for leading the future of healthcare,” he said.

The context

Abu Dhabi has made genomics a central part of its health strategy over the past decade. The emirate runs large-scale population health programs, including the Abu Dhabi Genome Program, which aims to sequence the genomes of UAE nationals and long-term residents to build a reference database for the region.

Boehringer Ingelheim is one of the world’s largest privately held pharmaceutical companies, with a strong research focus in several of the disease areas covered by this partnership, particularly cardiovascular disease, diabetes, and fibrotic conditions. Signing deals at BIO International is a well-established route for pharma companies to formalize research relationships, and this agreement fits a broader industry trend of large drugmakers partnering with regional health authorities to access diverse population data.

The deal also reflects growing competition among Gulf states to attract life sciences investment and establish themselves as research hubs, with Saudi Arabia, Qatar, and the UAE all pursuing similar strategies.

The post Abu Dhabi and Boehringer Ingelheim team up to advance precision medicine research appeared first on DH Arab.

The announcement matters because infrastructure has long been the missing piece for life sciences ambitions in the Gulf. Talent and funding are increasingly available, but access to specialist bench space and advanced equipment has been a real barrier, particularly for startups and early-stage companies that cannot justify the capital cost of building their own facilities. Biosphere Labs is a direct attempt to close that gap.

The facility sits within Masdar City’s HELM cluster, which launched in 2025. HELM, which stands for Health, Endurance, Longevity, and Medicine, is Abu Dhabi’s designated hub for pharmaceutical manufacturing, medical innovation and advanced biotechnology. Biosphere Labs adds shared, commercially available lab space to that mix, making the cluster more accessible to outside organizations and researchers.

How will it work?

Biosphere Labs operates as a shared infrastructure model. Rather than building and equipping a private lab, users pay for access to what they need, when they need it. The facility offers:

• Specialist bench space for individual researchers and teams
• Advanced laboratory equipment without the capital outlay of ownership
• Operational support to help teams hit the ground running
• Connections into Abu Dhabi’s wider life sciences network, including clinical, manufacturing and commercialization partners

Attentive Science is the initiator and day-to-day operator of the facility. The company says the model is built around one goal: letting scientists and biotech companies focus on their research from day one, rather than spending months setting up operations. The partnership with M42 adds clinical and healthcare expertise to the mix, which could prove valuable for companies working on diagnostics, therapeutics or precision medicine applications.

Why does it matter?

Shared lab models have proven effective in cities like Boston, London and Singapore, where they helped build dense, competitive biotech clusters by lowering the cost of entry for small companies and international teams testing a new market. Abu Dhabi is making a similar bet.

For international biotech companies thinking about the Middle East, Biosphere Labs reduces the friction of entering the region considerably. Instead of a multi-year process of setting up local operations, a company can move into ready-made lab space, access regional networks and start generating data relatively quickly. That is a meaningful change in the value proposition Abu Dhabi can offer.

There is also a broader signal here. The UAE has been investing heavily in life sciences as part of its economic diversification push, and Biosphere Labs is evidence that the country is moving past announcements and into actual infrastructure. The presence of organizations like Thermo Fisher Scientific, Oxford Nanopore Technologies and Insilico Medicine at Masdar City suggests the cluster is gaining credibility with global players.

The context

Biosphere Labs is part of a bigger pattern across the Gulf, where governments are trying to build knowledge-based industries to reduce dependence on oil revenues. Life sciences and biotech have become a priority target because they combine high-value jobs, intellectual property creation and long-term healthcare benefits.

Abu Dhabi has moved faster than most. The Abu Dhabi Biobank, which collects genomic data from the local population, gives researchers access to a dataset that is genuinely valuable for precision medicine research in non-Western populations, a segment of the global market that has historically been underserved by clinical research. That kind of asset, combined with shared lab access through Biosphere Labs, makes the proposition more concrete.

The HELM cluster model also draws on lessons from established biotech hubs. Co-locating research, manufacturing, clinical development and commercialization in one place reduces the friction that typically slows the journey from discovery to product. Whether Abu Dhabi can attract enough international talent and companies to make that model work at scale is still an open question, but Biosphere Labs is a step toward answering it.

The post Abu Dhabi opens its first shared biotech lab as Masdar City bets big on life sciences appeared first on DH Arab.

The agreement builds on an existing relationship between the two organizations, which already spans clinical research, health technology assessment, and policy work in innovative treatment areas. This new MoU expands that relationship into genomics and precision medicine.

The goal is to connect Abu Dhabi’s population-level genomic data with Novartis’s drug development and research expertise, with the aim of improving health outcomes for patients in the UAE and potentially beyond.

How will it work?

The MoU outlines three main areas of joint work:

• Genomics research: Both organizations will collaborate on research relevant to the UAE population, using data and insights from Abu Dhabi’s existing genomics infrastructure.
• Scientific capacity building: The partnership aims to strengthen local scientific capabilities, helping Abu Dhabi develop homegrown expertise in genomics and precision medicine.
• Advanced therapies: The two sides will explore how genomic insights can support the development and access of more targeted treatments.

The visit to Novartis’s San Diego site also included leadership meetings and discussions on future opportunities in biomedical research, suggesting the collaboration could expand further over time.

Why does it matter?

Abu Dhabi’s Emirati Genome Programme has already sequenced more than 900,000 genomes, making it one of the largest population genomics programs anywhere in the world. That scale is significant. Most genomic databases are dominated by European ancestry data, which limits how useful they are for diagnosing and treating people from other populations. A dataset of this size, focused on Emirati and UAE residents, could help address that gap.

Partnering with a global pharmaceutical company like Novartis gives Abu Dhabi a direct link between its genomic data and the drug development pipeline. That connection matters because sequencing genomes is only the first step. Turning that data into better treatments requires clinical expertise, research infrastructure, and the ability to run trials, all areas where Novartis brings experience.

Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, said the collaboration “accelerates the translation of research into solutions that can improve outcomes for patients and communities.” Mohamed Ezz Eldin, Head of Novartis GCC Cluster, said the partnership offers “an opportunity to support advances in genomics research, scientific capability building, and the future of precision medicine.”

The context

Abu Dhabi has been investing heavily in health innovation for several years. The Emirati Genome Programme launched with the ambition of sequencing the genomes of the entire Emirati population, and the 900,000-genome milestone shows that effort is well advanced. The emirate has also built out a broader ecosystem of research institutions, hospitals, and health technology companies designed to work together.

For Novartis, this deal fits a wider industry pattern. Major pharmaceutical companies are increasingly partnering with governments and health systems that hold large, well-characterized population datasets. Access to that kind of data can speed up target identification, improve clinical trial design, and support regulatory submissions. The UAE, with its relatively young and genetically distinct population, offers a dataset that is genuinely hard to replicate elsewhere.

The fact that the signing happened at BIO 2026, the biotech industry’s largest annual convention, also signals that both parties want this partnership to be visible. It positions Abu Dhabi as a serious player in global genomics, not just a regional one.

The post Abu Dhabi and Novartis team up on genomics research and precision medicine appeared first on DH Arab.